Table 1 Comparison between the study groups as regards the demographic data, clinical data, and medications
Demographic data | No POAF | POAF | P-value |
|---|---|---|---|
Count | 61 | 28 | |
Age (years) | 55.0 ± 6.4 | 58.7 ± 9.2 | 0.032 |
BMI (kg/m2) | 31.5 ± 4.1 | 33.0 ± 3.1 | 0.093 |
Risk factors | |||
Male gender | 40 (65.6%) | 18 (64.3%) | 0.906 |
HTN | 38 (62.3%) | 20 (71.4%) | 0.401 |
DM | 28 (45.9%) | 18 (64.3%) | 0.107 |
Smoking | 32 (52.5%) | 16 (57.1%) | 0.681 |
Clinical data | |||
NYHA class | |||
Class 1 | 42 (68.9%) | 19 (67.9%) | 0.925 |
Class 2 | 19 (31.1%) | 9 (32.1%) | |
CCS class | |||
Class 1 | 23 (37.7%) | 6 (21.4%) | 0.723 |
Class 2 | 29 (47.5%) | 21 (75%) | |
Class 3 | 9 (14.8%) | 1 (3.6%) | |
Heart rate (beat/min) | 76.4 ± 10.6 | 75.5 ± 10.8 | 0.708 |
Creatinine (mg/dL) | 0.90 ± 0.25 | 0.94 ± 0.26 | 0.726 |
CAD type | |||
Single vessel disease | 4 (6.6%) | 0 (0%) | 0.615 |
Two-vessel disease | 12 (19.7%) | 11 (39.3%) | |
Multi-vessel disease | 45 (73.7%) | 17 (60.7%) | |
Medication | |||
Aspirin | 61 (100%) | 28 (100%) | 1.000 |
Statins | 46 (75.4%) | 19 (67.9%) | 0.456 |
Nitrates | 56 (91.8%) | 16 (57.1%) | < 0.001 |
Beta blockers | 50 (82%) | 20 (71.4%) | 0.260 |
CCB | 4 (6.6%) | 2 (7.1%) | 1.000 |
Digoxin | 0 (0%) | 1 (3.6%) | 0.315 |
Diuretic | 14 (23%) | 3 (10.7%) | 0.173 |
ACEI or ARB | 46 (75.4%) | 18 (64.3%) | 0.278 |